Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance

REFERENCES

• Achira M, Suzuki H, Ito K, Sugiyama Y. (1999). Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharm. Sci. 1:14–19.
   Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413–420.
   PubMed Web of Science ®Google Scholar
• Ando H, Yanagihara H, Sugimoto K, Hayashi Y, Tsuruoka S, Takamura T. (2005). Daily rhythms of P-glycoprotein expression in mice. Chronobiol. Int. 22:655–665.
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Beijnen JH, Brouwer KR, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O. (2000). Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6:4416–4421.
   PubMed Web of Science ®Google Scholar
• Belanger PM, Bruguerolle B, Labrecque G. (1997). Rhythms in pharmacokinetics: absorption, distribution, metabolism, and excretion. In Redfern P, Lemmer B (eds.). Physiology and pharmacology of biological rhythms. Berlin: Springer, 177–204.
   Google Scholar
• Bramlage P, Schindler C. (2010). Differences in pharmacology and their translation into differences in clinical efficacy—a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opin. Pharmacother. 11:521–535.
   PubMed Web of Science ®Google Scholar
• Bruguerolle B. (2008). Clinical chronopharmacology in the elderly. Chronobiol. Int. 25:1–15.
   PubMed Web of Science ®Google Scholar
• Bruguerolle B, Bouvenot G, Bartolin R, Manolis J. (1988). Chronopharmacokinetics of digoxin in patients over 70 years of age. Therapie 43:251–253.
   PubMed Web of Science ®Google Scholar
• Claudel T, Cretenet G, Saumet A, Gachon F. (2007). Crosstalk between xenobiotics metabolism and circadian clock. FEBS Lett. 581:3626–3633.
   PubMed Web of Science ®Google Scholar
• Doluisio JT, Billups NF, Dittert LW, Sugita ET, Swintosky JV. (1969). Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. J. Pharm. Sci. 58:1196–200.
   PubMed Web of Science ®Google Scholar
• Dressler C. (2002). Interactions of losartan and its major metabolite EXP3174 with membrane transporters in vitro, in situ, and in vivo. PhD Dissertation, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
   Google Scholar
• Erol K, Kilic FS, Batu OS, Yildirim E. (2001). Morning-evening administration time differences in digoxin kinetics in healthy young subjects. Chronobiol. Int. 18:841–849.
   PubMed Web of Science ®Google Scholar
• Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, Li Q, Lei HP, Jiang F, Hu DL, Huang YF, Zhou HH. (2009). Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann. Pharmacother. 43:944–949.
   PubMed Web of Science ®Google Scholar
• Fischer V, Rodríguez-Gascón A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE. (1998). The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26:802–811.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Manabe S, Ohashi Y, Sharyo S, Kimura K, Mori Y. (1999). Daily fluctuation of 7-alkoxycoumarin O-dealkylase activities in the liver of male F344 rats under ad libitum-feeding or fasting condition. Toxicol. Lett. 108:11–16.
   PubMedGoogle Scholar
• Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. (2006). The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4:25–36.
   PubMed Web of Science ®Google Scholar
• Goo RH, Moore JG, Greenberg E, Alazraki NP. (1987). Circadian variation in gastric emptying of meals in humans. Gastroenterology 93:515–518.
   PubMed Web of Science ®Google Scholar
• Hanafy A. (2001). Transport inhibition and induction as sources for absorption- and disposition-related drug-drug interactions: talinolol as model substrate for ABC transporter P-glycoprotein. PhD Dissertation, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
   Google Scholar
• Hanafy A, Langguth P, Spahn-Langguth H. (2001). Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur. J. Pharm. Sci. 12:405–415.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Ushijima K, Ando H, Yanagihara H, Ishikawa E, Tsuruoka S, Sugimoto K, Fujimura A. (2010). Influence of a time-restricted feeding schedule on the daily rhythm of abcb1a gene expression and its function in rat intestine. J. Pharmacol. Exp. Ther. 335:418–423.
   PubMed Web of Science ®Google Scholar
• Ho KJ, Drummond JL. (1975). Circadian rhythm of biliary excretion and its control mechanisms in rats with chronic biliary drainage. Am. J. Physiol. 229:1427–1437.
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Aleksunes LM. (2010). Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 62:1–96.
   PubMed Web of Science ®Google Scholar
• Lemmer B. (1999). Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol. 51:887–890.
   PubMed Web of Science ®Google Scholar
• Lemmer B, Bruguerolle B. (1994). Chronopharmacokinetics. Are they clinically relevant? Clin. Pharmacokinet. 26:419–427.
   PubMed Web of Science ®Google Scholar
• Lemmer B, Nold G. (1991). Circadian changes in estimated hepatic blood flow in healthy subjects. Br. J. Clin. Pharmacol. 32:627–629.
   PubMed Web of Science ®Google Scholar
• Lemmer B, Caspari-Irving G, Weimer R. (1981). Strain-dependency in motor activity and in concentration and turnover of catecholamines in synchronized rats. Pharmacol. Biochem. Behav. 15:173–178.
   PubMed Web of Science ®Google Scholar
• Lemmer B, Nold G, Behne S, Kaiser R. (1991). Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol. Int. 8:485–494.
   PubMed Web of Science ®Google Scholar
• Lemmer B, Dressler C, Okyar A, Baktir G, Spahn-Langguth H. (2004). Circadian variations in effective permeabilities of talinolol and losartan in rats: metabolism- or transport-related? Naunyn Schmiedeberg. Arch. Pharmacol. 369(Suppl 1):R103/412.
   Google Scholar
• Lévi F, Schibler U. (2007). Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47:593–628.
   PubMed Web of Science ®Google Scholar
• Lévi F, Metzger G, Massari C, Milano G. (2000). Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38:1–21.
   PubMed Web of Science ®Google Scholar
• Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. (2010). Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50:377–419.
   PubMed Web of Science ®Google Scholar
• MacLean C, Moenning U, Reichel A, Fricker G. (2008). Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab. Dispos. 36:1249–1254.
   PubMed Web of Science ®Google Scholar
• Martin C, Dutertre-Catella H, Radionoff M, Debray M, Benstaali C, Rat P, Thevenin M, Touitou Y, Warnet JM. (2003). Effect of age and photoperiodic conditions on metabolism and oxidative stress related markers at different circadian stages in rat liver and kidney. Life Sci. 73:327–335.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Higashi Y, Matsunaga N, Koyanagi S, Ohdo S. (2008). Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology 135:1636–1644.
   PubMed Web of Science ®Google Scholar
• Oertel R, Richter K, Trausch B, Berndt A, Gramatte T, Kirch W. (1994). Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J. Chromatogr. B 660:353–363.
   PubMed Web of Science ®Google Scholar
• Okyar A. (2004). Investigation of interaction between talinolol-vinblastine and talinolol-atorvastatin through P-glycoprotein. Ph.D. dissertation, Department of Pharmacology, Institute of Health Science, Istanbul University, Istanbul, Turkey.
   Google Scholar
• Okyar A, Filipski E, Dulong S, Ahowesso C, Li XM, Levi F. (2009). Rhythmic intestinal drug elimination via ABC transporters: a potential determinant of anticancer drugs chronopharmacology. In 11th Congress of European Biological Rhythm Society, Strasbourg, France. August 22–29. Program and abstract book, 153.
   Google Scholar
• Okyar A, Piccolo E, Ahowesso C, Filipski E, Hossard V, Guettier C, La Sorda R, Tinari N, Iacobelli S, Lévi F. (2011). Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS ONE 6(6):e20393.
   Google Scholar
• Pons M, Tranchot J, L'Azou B, Cambar J. (1994). Circadian rhythms of renal hemodynamics in unanesthetized, unrestrained rats. Chronobiol. Int. 11:301–308.
   PubMed Web of Science ®Google Scholar
• Pons M, Schnecko A, Witte K, Lemmer B, Waterhouse JM, Cambar J. (1996). Circadian rhythms in renal function in hypertensive TGR(mRen-2)27 rats and their normotensive controls. Am. J. Physiol. 271:R1002–R1008.
   PubMedGoogle Scholar
• Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911–1929.
   PubMed Web of Science ®Google Scholar
• Sachs L. (1978). Applied statistics (pp. 230–235). Berlin: Springer.
   Google Scholar
• Sandström R, Lennernäs H. (1999). Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats. Drug Metab. Dispos. 27:951–958.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I. (2009). Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res. 26:560–567.
   PubMed Web of Science ®Google Scholar
• Sinko P.J, Leesman G.D, Amidon G.L. (1991). Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8:979–988.
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Langguth P. (2001). Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12:361–367.
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Baktır G, Radschuweit A., Okyar A., Terhaag B., Ader P, Hanafy A, Langguth P. (1998). P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:16–24.
   PubMed Web of Science ®Google Scholar
• Stearns A, Balakrishnan A, Rhoads D, Ashley S. (2008). Diurnal rhytmicity in the transcription of jejunal drug transporters. J. Pharm. Sci. 108:144–148.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesmann MM. (2006). Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 3:219–234.
   Google Scholar
• Therapeutic Systems Research Lab. Inc. http://www.tsrlinc.com. Accessed October 28, 2011.
   Google Scholar
• Trausch B, Oertel R, Richter K, Gramatte T. (1995). Disposition and bioavailability of the β1-adrenoceptor antagonist talinolol in man. Biopharm. Drug Dispos. 16:403–414.
   PubMed Web of Science ®Google Scholar
• Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:514–522.
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22:11–23.
   PubMed Web of Science ®Google Scholar
• Zhang YK, Yeager RL, Klaassen CD. (2009). Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab. Dispos. 37:106–115.
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Martin M, Placidi M, Cano JP, Rahmani R. (1990). In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine. Eur. J. Drug Metab. Pharmacokinet. 15:323–332.
   PubMedGoogle Scholar
• Zschiesche M, Lemma GL, Klebingat KJ, Franke G, Terhaag B, Hoffmann A, Gramatté T, Kroemer HK, Siegmund W. (2002). Stereoselective disposition of talinolol in man. J. Pharm. Sci. 91:303–311.
   PubMed Web of Science ®Google Scholar